Review: Aldosterone blockade reduces mortality in patients with left ventricular dysfunction

Liu, Peter; Ezekowitz, J. A.
August 2009
ACP Journal Club;8/18/2009, Vol. 151 Issue 2, p7
Academic Journal
The article reports that aldosterone blockade reduces mortality in patients with left ventricular dysfunction and heart failure or post myocardial infarction but is associated with adverse renal and electrolyte abnormalities. With appropriate monitoring, the benefits seen in these trials should translate into real-life practice.


Related Articles

  • Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie // New England Journal of Medicine;4/3/2003, Vol. 348 Issue 14, p1309 

    Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Aldosterone use in heart failure.  // Infectious Disease Alert;Dec2009 Pharmacology Watch Suppleme, p1 

    The article discusses research on the clinical use of aldosterone for heart failure (HF). It references a study published in the 2009 issue of the "Journal of the American Medical Association." The study included 43,000 patients who were hospitalized due to HF between 2005 and 2007. Study...

  • Inspra.  // Formulary;Nov2002, Vol. 37 Issue 11, p553 

    Focuses on Pharmacia & Upjohn Inc.'s aldosterone blocker Inspra, generic name eplerenone. Use of Inspra for treating hypertension; Effectiveness and safety of the drug; Recommended dosage.

  • Erratum.  // Surgical Endoscopy;Dec2004, Vol. 18 Issue 12, p1828 

    Presents a correction on an article focusing on the effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure in pigs, published in a previous issue of the journal "Surgical Endoscopy."

  • Fresh from the pipeline: Eplerenone. Brown, Ruth; Quirk, Jeremy; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Mar2003, Vol. 2 Issue 3, p177 

    In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the rennin-angiotensin-aldosterone system?

  • Efficacy of spironolactone therapy in patients with heart failure with normal ejection fraction: The Authors' reply. Yip, Gabriel W. K.; Sanderson, John E. // Heart;May2010, Vol. 96 Issue 10, p791 

    A response to a letter to the editor about an article on the efficacy of aldosterone antagonists for the treatment of heart failure with normal ejection fraction is presented.

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard? Jewell, Coty W.; Watson, Linley E.; Mock, Jonathan; Dostal, David E. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2006, Vol. 4 Issue 2, p129 

    Aldosterone is a mineralocorticoid primarily produced in the zona glomerulosa of the adrenal gland. For many years, aldosterone (Aldo) was thought to have its sole site of action in the kidney, where it regulated sodium excretion and potassium reabsorption. It is now known that Aldo is produced...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics